A preclinical study showed that another FAK inhibitor, AMP945, in combination with FOLFIRINOX, can significantly increase the survival of pancreatic cancer-bearing mice with patient-derived xenograft (PDX) models by increasing tumor cell apoptosis and reducing FAK Y397 phosphorylation [135]. This evidence concerns the gene PTK2 and neoplasm.